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Abstract
Hypoglycemia is associated with increased risk of cardiovascular adverse clinical outcomes. There is evidence that impaired
glucose tolerance (IGT) is associated with cardiovascular morbidity and mortality. Whether IGT individuals have
asymptomatic hypoglycemia under real-life conditions that are related to early atherosclerosis is unknown. To this aim,
we measured episodes of hypoglycemia during continuous interstitial glucose monitoring (CGM) and evaluated their
relationship with early manifestation of vascular atherosclerosis in glucose tolerant and intolerant individuals. An oral
glucose tolerance test (OGTT) was performed in 79 non-diabetic subjects. Each individual underwent continuous glucose
monitoring for 72 h. Cardiovascular risk factors and ultrasound measurement of carotid intima-media thickness (IMT) were
evaluated. IGT individuals had a worse cardiovascular risk profile, including higher IMT, and spent significantly more time in
hypoglycemia than glucose-tolerant individuals. IMT was significantly correlated with systolic (r=0.22; P=0.05) and diastolic
blood pressure (r=0.28; P=0.01), total (r=0.26; P=0.02) and LDL cholesterol (r=0.27; P=0.01), 2-h glucose (r=0.39;
P,0.0001), insulin sensitivity (r=20.26; P=0.03), and minutes spent in hypoglycemia (r=0.45; P,0.0001). In univariate
analyses adjusted for gender, minutes spent in hypoglycemia were significantly correlated with age (r=0.26; P=0.01), waist
circumference (r=0.33; P=0.003), 2-h glucose (r=0.58; P,0.0001), and 2-h insulin (r=0.27; P=0.02). In a stepwise
multivariate regression analysis, the variables significantly associated with IMT were minutes spent in hypoglycemia
(r
2=0.252; P,0.0001), and ISI index (r
2=0.089; P=0.004), accounting for 34.1% of the variation. Episodes of hypoglycemia
may be considered as a new potential cardiovascular risk factor for IGT individuals.
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Introduction
Hypoglycemia is a well-known side effect of glucose-lowering
therapy in both type 1 and type 2 diabetes mellitus, and becomes
more prevalent with treatment intensification [1,2]. Hypoglycemia
has been strongly associated with increased risk of cardiovascular
adverse clinical outcomes [1–4]. Hypoglycemia may promote
localized vasoconstriction by inducing release of epinephrine, it
may also induce pro-inflammatory, platelet aggregatory, anti-
fibrinolytic, and pro-thrombotic changes, and stimulate stress
responses leading to endothelial damage, and vascular atheroscle-
rosis [5,6]. There is evidence that impaired glucose tolerance
(IGT) is associated with cardiovascular morbidity and mortality
[7–9]. Subjects with IGT are characterized by a late insulin
response to an oral glucose tolerance test (OGTT), that results in a
progressive raise of plasma insulin from 60 to 120 min [10,11]. In
these subjects, a persistent increase in insulin levels after a meal
may result in late postprandial hypoglycemia. Whether IGT
individuals have asymptomatic hypoglycemia under real-life
conditions that are related to early atherosclerosis is unknown.
To this aim, we measured episodes of hypoglycemia during
continuous interstitial glucose monitoring (CGM) and evaluated
their relationship with a early manifestation of vascular athero-
sclerosis, assessed as carotid intima–media thickness (IMT) in
glucose tolerant and intolerant individuals.
Materials and Methods
Seventy-nine non-diabetic Caucasian subjects were consecu-
tively recruited at the Department of Internal Medicine of the
University of Rome-Tor Vergata. Recruitment mechanisms
include word-of-mouth, fliers, and newspaper advertisements.
Subjects, aged 23–70 years, were excluded if they had history of
cardiovascular disease, including peripheral atherosclerosis,
chronic gastrointestinal diseases associated with malabsorption,
chronic pancreatitis, history of any malignant disease, history of
alcohol or drug abuse, liver or kidney failure, or received
treatments able to modify glucose metabolism including glucose-
lowering, lipid-lowering and antihypertensive therapy. None of
the subjects were taking anti-platelet medications. All subjects
underwent an anthropometrical evaluation and readings of clinic
blood pressure were obtained in the left arm of the supine
patients, after 5 min of quiet rest, with a mercury sphygmoma-
nometer. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were recorded at the first appearance (phase I)
and at the disappearance (phase V) of Korotkoff sounds. Blood
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three consecutive measurements obtained at 3-mins intervals.
After 12-h fasting, a 75 g OGTT was performed with 0, 30, 60,
90 and 120 min sampling for plasma glucose and insulin. The
Matsuda index of insulin sensitivity (ISI) was calculated as
reported [12]. Each individual underwent CGM for 72 h with a
Medtronic MiniMed, CA, a Holter-style sensor system designed
to continuously monitor interstitial fluid glucose levels within a
range of 40–400 mg/dl. The sensor was inserted in the
subcutaneous abdominal fat tissue in accordance with the
manufacturers’ instructions. Initial sensor failure was defined as
unsuccessful calibration on repeated attempst over 1 hour,
current and voltage signals fluctuating rapidly or out of range,
or haemorrhage at the insertion site, when the sensor was
removed and replaced with a new sensor at a different site.
Subjects were taught calibration procedures and instructed to
calibrate whenever alerted by the device. According to the
accuracy criteria defined by the manufacturer, in our study CGM
results were considered valid if at least three calibrations were
performed during 24-h of monitoring. Sensor insertions were
performed in hospital, but subjects were dismissed, and
encouraged to maintain their usual daily diet and activities
during the monitoring period. CGM data were analyzed using
Medtronic-MiniMed Solutions Software version 3.0b. As an
indicator of hypoglycemia, the time spent below 70 mg/dl blood
glucose [13] were calculated during the 72 h glucose monitoring
period.
IMT of the common carotid artery was measured by ATL
HDI 3000 ultrasound system (Advanced Technology Laborato-
ries, Bothell, WA) equipped with a 5 MHz linear array
transducer as previously described [14,15]. This system provides
high resolution ultrasonic images with 0.3 mm axial resolution.
The subjects were examined in the supine position. To avoid
variability during the cardiac cycle, the images were frozen in
the end-diastolic phase. IMT was determined only from the far
wall of the artery, because it is known to have a higher precision
than the near arterial wall. Manual measurements were
conducted in plaque-free portions of the 10-mm linear segment
proximal to the carotid bulb. For each patient two measurements
were performed bilaterally, and the values were averaged, which
presented the mean of IMT of the common carotid artery. No
plaques, defined as a clearly isolated focal thickening of the
intima-media layer with a thickness .1.3 mm, were observed in
any individuals. Ultrasound study was performed by an
experienced examiner who was unaware of the subjects’ clinical
and laboratory findings.
The protocol was approved by the institutional ethical
committee the University of Rome-Tor Vergata and informed
written consent was obtained from each participant in accordance
with principles of the Declaration of Helsinki.
Statistical analysis
Continuous data are expressed as means 6SD. Categorical
variables were compared by x
2 test. The coefficient of variation
(CV) of interstitial glucose during CGM was calculated as the ratio
of the standard deviation to the mean. Phenotypic differences
between groups were tested after adjusting for age, and gender
using a general linear model. Partial correlation coefficients
adjusted for age and gender were computed between variables.
Relationships between variables were sought by stepwise multi-
variate linear regression analysis to assess their independent
contribution to IMT. A P value,0.05 was considered statistically
significant. All analyses were performed using SPSS software
Version 16.0.
Results
The anthropometric and cardio-metabolic characteristics of the
study groups are shown in Table 1. IGT individuals were older,
more frequently smokers, and had significantly higher lipid levels,
blood pressure, 2-hour post-load plasma glucose and insulin levels,
and carotid IMT, as well as lower insulin sensitivity, assessed by
the ISI index, as compared with glucose tolerant individuals
(Table 1). IGT individuals spent significantly more time in
hypoglycemia as compared with glucose tolerant individuals
(Table 1 and Figures 1 and 2). Mean interstitial glucose levels
during CGM did not differ between the two groups of subjects.
CV of interstitial glucose during CGM was not significantly higher
in IGT individuals. In univariate analyses adjusted for gender,
minutes spent in hypoglycemia were significantly correlated with
age (r=0.26; P=0.01), waist circumference (r=0.33; P=0.003), 2-
h post-load plasma glucose (r=0.58; P,0.0001), and 2-h post-load
insulin (r=0.27; P=0.02). In univariate analyses adjusted for
gender and age, carotid IMT was significantly correlated with
systolic and diastolic blood pressure, total and LDL cholesterol, 2-
h post-load plasma glucose, insulin sensitivity, and minutes spent
in hypoglycemia (Table 2). A stepwise multivariate regression
analysis in a model including age, gender, body mass index, waist
circumference, smoking habits, lipid levels, blood pressure, fasting
and 2-hour post-load plasma glucose, fasting and 2-hour post-load
insulin levels, ISI index, and minutes spent in hypoglycemia
showed that the two variables that remained significantly
associated with carotid IMT were minutes spent in hypoglycemia
(partial r
2=0.252; P,0.0001), and ISI index (partial r
2=0.089;
P=0.004), accounting for 34.1% of the variation.
Discussion
To the best of our knowledge, this is the first study evaluating
the association between episodes of hypoglycemia, assessed by
CGM under real-life conditions, and preclinical atherosclerosis in
non-diabetic subjects with different degrees of glucose tolerance.
Our findings suggest that IGT individuals have asymptomatic
episodes of hypoglycemia and spend more than 2 hrs per day
below the hypoglycemia threshold of ,70 mg/dl. The hypogly-
cemic episodes were significantly correlated with 2-h post-load
plasma glucose and insulin levels, thus raising the possibility that
hypoglycemia occurs during the late post-prandial period as a
consequence of a prolonged release of insulin in response to
elevated glucose levels.
Performance assessment of the Medtronic-MiniMed CGM
system has demonstrated that it has an acceptable clinical
accuracy, with 96.6% of paired sensor-blood glucose self
monitoring readings falling in the ‘clinically acceptable’ zones A
and B of the Clarke error grid for type 1 diabetic subjects [16]. As
compared with blood glucose self monitoring, CGMS detected
significantly more episodes of hypoglycemia and post-prandial
hyperglycemia, while total duration of hyperglycemia, blood
glucose oscillations and day-to-day variability were assessed with
a similar accuracy with the two methods [16]. Additionally, no
statistically significant differences between Medtronic-MiniMed
CGM system measures and self-monitoring capillary plasma
glucose readings have been observed in non-diabetic individuals
[17].
The measurement of IMT of the common carotid artery is a
well accepted method to monitor the early stages of atherosclerosis
and IMT increase precedes the development of plaque and
stenosis in the arterial wall. Furthermore, IMT of the common
carotid artery has been shown to be related to prevalent and
incident cardiovascular disease [18]. There is incomplete infor-
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found that the time spent in hypoglycemia was the strongest
determinant of carotid IMT. Alterations in vascular tone,
coagulation, fibrinolysis, and inflammation associated with
repeated episodes of hypoglycemia may be associated with the
induction and progression of atherosclerosis [5,6]. These findings
Figure 1. Twenty-four-hour glucose profiles of 10 representative individuals with NGT. Dashed line indicates the 70 mg/dl glucose
threshold.
doi:10.1371/journal.pone.0028312.g001
Table 1. Anthropometric and biochemical characteristics of the study subjects.
NGT subjects IGT subjects P
Number (male/female) 36 (16/20) 43 (27/16) NS
Age (yrs) 50611 (27–70) 5869 (23–70) ,0.01*
BMI (kg/m
2) 27.465.7 (20.3–41.7) 27.063.5 (19.9–34.3) NS
Waist circumference (mm)9 0 617 (62–140) 96613 (65–129) NS
Smokers (%) 12 (33.3%) 24 (55.8%) ,0.05
SBP (mmHg) 125617 (95–170) 135616 (100–180) ,0.05
DBP (mmHg) 77612 (55–100) 8368 (65–100) ,0.05
Total Cholesterol (mg/dl) 191637 (110–270) 207628 (142–271) ,0.05
LDL Cholesterol (mg/dl) 118637 (22–200) 133627 (77–197) ,0.05
HDL Cholesterol (mg/dl) 48611 (27–69) 43611 (20–69) ,0.05
Triglyceride (mg/dl) 123642 (49–190) 152650 (52–273) ,0.05
Fasting Glucose (mgl/dl) 10469 (79–124) 105611 (83–125) NS
2-h glucose (mg/dl)1 0 8 618 (65–139) 176619 (144–199) ,0.0001
Fasting Insulin (mU/ml) 1367 (3–37) 1267 (1–25) NS
2-h Insulin (mU/ml) 67657 (19–308) 102681 (27–451) ,0.05
Matsuda index/ISI 5.263.5 (1.9–18.7) 3.361.2 (0.9–6.3) ,0.05
Intima-media thickness (mm) 0.7360.09 (0.6–0.9) 0.8760.13 (0.45–1.0) ,0.0001
Minutes per day in hypoglycemia 35612 (5–59) 130674 (5–250) ,0.0001
Mean interstitial glucose during CGM 98622 (74–137) 109626 (74–234) NS
Coefficient of variation (CV) of interstitial glucose
during CGM
22 (7–61) (95% CI 25 to 32) 28 (10–58) (95% CI 24 to 31)
Data are means 6 SD. Data in brackets are ranges of minimum and maximum value. Data of CV of interstitial glucose during CGM are reported as the mean, the range
and the 95% CI for comparison between the groups. Categorical variables were compared by x2 test. P values refer to results after analyses with adjustment for age, and
gender using a general linear model.
*P values refer to results after analysis with adjustment for gender using a general linear model. BMI: body mass index; SBP=systolic blood pressure; DBP=diastolic
blood pressure. NS=Not significant.
doi:10.1371/journal.pone.0028312.t001
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mia could be considered as a new potential cardiovascular risk
factor in IGT individuals. However, in the absence of data
determining the impact of these episodes of hypoglycemia on
major cardiovascular outcomes, the present results cannot
establish whether episodes of hypoglycemia are part of normal
variability in IGT individuals or whether such episodes affect the
risk of progression to cardiovascular disease.
Although observational studies have reported a strong associ-
ation between hyperglycemia and increased risk for cardiovascular
disease in individuals with type 2 diabetes, the results of recent
interventional randomized controlled trials in establishing the
benefit of intensive glycemic control on cardiovascular outcomes
have been elusive [19–22]. The glycemic control arm of the Action
to Control Cardiovascular Risk in Diabetes (ACCORD) was
halted early because of higher mortality in the intensive arm
compared with the standard arm [20]. The underlying reason of
these findings was unclear at the time of the intervention stop,
although several hypotheses were raised, including severe
hypoglycemia. In a post hoc analysis of the ACCORD study, it
was found that patients who experienced severe hypoglycemia,
regardless of study arm, showed an increased risk of death [23].
Accordingly, in the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled Evaluation
(ADVANCE) study, severe hypoglycemia was associated with
increased risk of cardiovascular events, and death from both
cardiovascular and non-cardiovascular causes in patients assigned
to either standard or intensive glucose control [24]. The
detrimental role of hypoglycemia is further supported by a
retrospective cohort study including data from the UK General
Practice Research Database showing that both low and high mean
HbA1c values were associated with increased all-cause mortality
according to an U-shaped pattern of risk [25].
This study has some strengths including the measurement of
plasma glucose during an OGTT in drug-naı ¨ve individuals thus
excluding the confounding effect of medications affecting glucose,
and assessment of CGM under real-life conditions. Nonetheless,
the present study has limitations. CGM has intrinsic limitations
since it measures interstitial fluid rather than blood glucose levels.
In addition, OGTTs were performed once, and, thus, intra-
individual variation in plasma glucose levels cannot be taken into
account leading to possible misclassification of some subjects with
IGT. The cross-sectional design of the study does not provide
insights into the time course of the development of cardiovascular
Figure 2. Twenty-four-hour glucose profiles of 10 representative individuals with IGT. Dashed line indicates the 70 mg/dl glucose
threshold.
doi:10.1371/journal.pone.0028312.g002
Table 2. Univariate correlations between IMT and
anthropometric and biochemical variables.
IMT P
rP
Age (yrs) 0.29 ,0.01*
BMI (kg/m
2) 0.13 NS
Waist circumference (mm) 0.21 NS
SBP (mmHg) 0.22 ,0.05
DBP (mmHg) 0.28 ,0.01
Total Cholesterol (mg/dl) 0.26 ,0.05
LDL Cholesterol (mg/dl) 0.27 ,0.01
HDL Cholesterol (mg/dl) 20.08 NS
Triglyceride (mg/dl) 0.07 NS
Fasting Glucose (mgl/dL) 0.03 NS
2-h glucose (mg/dl) 0.39 ,0.0001
Fasting Insulin (mU/ml) 0.18 NS
2-h Insulin (mU/ml) 0.13 NS
Matsuda index/ISI 20.26 ,0.05
Minutes per day in hypoglycemia (,70 mg/dl) 0.45 ,0.0001
Mean interstitial glucose during CGM 0.12 NS
Coefficient of variation (CV) of interstitial glucose during CGM 0.08 NS
Partial correlation coefficients adjusted for age and gender were computed
between variables. P values refer to results after analyses with adjustment for
age, and gender.
*P values refer to results after analysis with adjustment for gender. BMI=Body
Mass Index, SBP=systolic blood pressure; DBP=diastolic blood pressure.
doi:10.1371/journal.pone.0028312.t002
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relationships can be made. Finally, the present findings are only
based on Caucasian individuals, and results might vary as a
function of ethnic group.
In conclusion, since hypoglycemic episodes are considered to be
among the mediators of cardiovascular events, our findings
indicate that exposure to glucose levels below the hypoglycemia
threshold remains under-appreciated in individuals with IGT. The
present results suggest that it is common for persons who are
classified as ‘pre-diabetic’’ to experience transient hypoglycemia
during everyday circumstances.
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